Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism


Author index

Page Path
Hye Soo Chung  (Chung HS) 5 Articles
Hashimoto Thyroiditis and Mortality in Patients with Differentiated Thyroid Cancer: The National Epidemiologic Survey of Thyroid Cancer in Korea and Meta-Analysis
Injung Yang, Jae Myung Yu, Hye Soo Chung, Yoon Jung Kim, Yong Kyun Roh, Min Kyu Choi, Sung-ho Park, Young Joo Park, Shinje Moon
Endocrinol Metab. 2024;39(1):140-151.   Published online January 3, 2024
  • 1,566 View
  • 64 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Many studies have shown that Hashimoto’s thyroiditis (HT) acts as a protective factor in differentiated thyroid cancer (DTC), but little is known about its effects on mortality. Therefore, this study was performed to reveal the prognosis of HT on mortality in patients with DTC.
This study included two types of research results: retrospective cohort study using the National Epidemiologic Survey of Thyroid cancer (NEST) in Korea and meta-analysis study with the NEST data and eight selected studies.
Of the 4,398 patients with DTC in NEST, 341 patients (7.8%) died during the median follow-up period of 15 years (interquartile range, 12.3 to 15.6). Of these, 91 deaths (2.1%) were related to DTC. HT was associated with a smaller tumor size and less aggressive DTC. In Cox regression analysis after adjusting for age and sex, patients with HT showed a significantly lower risk of all-cause death (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.52 to 0.96) and DTC-related death (HR, 0.33; 95% CI, 0.14 to 0.77). The analysis with inverse probability of treatment weight data adjusted for age, sex, and year of thyroid cancer registration showed similar association. The meta-analysis showed that patients with HT showed a lower risk of all-cause mortality (risk ratio [RR], 0.24; 95% CI, 0.13 to 0.47) and thyroid cancer-related mortality (RR, 0.23; 95% CI, 0.13 to 0.40) in comparison with patients without HT.
This study showed that DTC co-presenting with HT is associated with a low risk of advanced DTC and presents a low risk for all-cause and DTC-related death.


Citations to this article as recorded by  
  • Germline polymorphisms of the NOD2 pathway may predict the effectiveness of radioiodine in differentiated thyroid cancer treatment
    M. Borowczyk, M. Kaczmarek-Ryś, S. Hryhorowicz, M. Sypniewski, D. Filipowicz, P. Dobosz, M. Oszywa, M. Ruchała, K. Ziemnicka
    Journal of Endocrinological Investigation.2024;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
Shinje Moon, Jibeom Lee, Hye Soo Chung, Yoon Jung Kim, Jae Myung Yu, Sung Hoon Yu, Chang-Myung Oh
Endocrinol Metab. 2021;36(3):647-660.   Published online June 18, 2021
  • 6,607 View
  • 308 Download
  • 14 Web of Science
  • 16 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight and obese people. This study aimed to systematically analyze the effects of liraglutide on body weight and other cardiometabolic parameters.
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
We included 31 studies with 8,060 participants for this meta-analysis. The mean difference (MD) between the liraglutide group and the placebo group was −4.19 kg (95% confidence interval [CI], −4.84 to −3.55), with a −4.16% change from the baseline (95% CI, −4.90 to −3.43). Liraglutide treatment correlated with a significantly reduced body mass index (MD: −1.55; 95% CI, −1.76 to −1.34) and waist circumference (MD: −3.11 cm; 95% CI, −3.59 to −2.62) and significantly decreased blood pressure (systolic blood pressure, MD: −2.85 mm Hg; 95% CI, −3.36 to −2.35; diastolic blood pressure, MD: −0.66 mm Hg; 95% CI, −1.02 to −0.30), glycated hemoglobin (MD: −0.40%; 95% CI, −0.49 to −0.31), and low-density lipoprotein cholesterol (MD: –2.91 mg/dL; 95% CI, −5.28 to −0.53; MD: −0.87% change from baseline; 95% CI, −1.17 to −0.56).
Liraglutide is effective for weight control and can be a promising drug for cardiovascular protection in overweight and obese people.


Citations to this article as recorded by  
  • Pharmacotherapy for obesity: moving towards efficacy improvement
    Walmir Coutinho, Bruno Halpern
    Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
  • Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic
    Bruno Silvestrini, Mauro Silvestrini, Mayank Choubey
    Journal of Obesity.2024; 2024: 1.     CrossRef
  • Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model
    Katerina Horska, Jan Kucera, Eva Drazanova, Gabriela Kuzminova, Petra Amchova, Maria Hrickova, Jana Ruda-Kucerova, Silje Skrede
    Biomedicine & Pharmacotherapy.2024; 176: 116763.     CrossRef
  • Association between weight loss and cardiovascular outcomes and mortality in Korea: A nationwide cohort study
    So Yoon Kwon, Gyuri Kim, Seohyun Kim, Jae Hyeon Kim
    Diabetes Research and Clinical Practice.2024; 214: 111767.     CrossRef
  • Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
    Yilin Li, Rong Lei, Honglin Lei, Qin Xiong, Fengjiao Xie, Chengjiao Yao, Peimin Feng
    European Journal of Gastroenterology & Hepatology.2023; 35(1): 1.     CrossRef
  • Recommendations for the prevention and management of obesity in the Iraqi population
    Hussein Ali Nwayyir, Esraa Majid Mutasher, Osama Mohammed Alabid, Muthana Abdulrazzaq Jabbar, Wefak Hasan Abdulraheem Al-Kawaz, Haider Ayad Alidrisi, Majid Alabbood, Muhammed Chabek, Munib AlZubaidi, Lujain Anwar Al-khazrajy, Ibtihal Shukri Abd Alhaleem,
    Postgraduate Medicine.2023; 135(5): 425.     CrossRef
  • A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
    Fatma Haddad, Ghadeer Dokmak, Maryam Bader, Rafik Karaman
    Life.2023; 13(4): 1012.     CrossRef
  • Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
    Juyoung Shin, Raeun Kim, Hun-Sung Kim
    Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 49.     CrossRef
  • The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
    Pejman Rohani, Nasser Malekpour Alamdari, Seyedeh Elaheh Bagheri, Azita Hekmatdoost, Mohammad Hassan Sohouli
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials
    Hao Gou, Yiman Zhai, Junjun Guo
    European Journal of Pediatrics.2023; 182(11): 5095.     CrossRef
  • Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
    Ping Zhong, Hai Zeng, Miaochun Huang, Wenbin Fu, Zhixia Chen
    Endocrine.2022; 75(3): 718.     CrossRef
  • Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
    David C. W. Lau, Rachel L Batterham, Carel W. le Roux
    Expert Review of Clinical Pharmacology.2022; 15(3): 251.     CrossRef
  • Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine
    Peter Manu, Cristina-Mihaela Lăcătuşu, Liliana M. Rogozea, Simona Cernea
    American Journal of Therapeutics.2022; 29(4): e410.     CrossRef
  • GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
    Katerina Horska, Jana Ruda-Kucerova, Silje Skrede
    Trends in Endocrinology & Metabolism.2022; 33(9): 628.     CrossRef
  • Targeting skeletal muscle mitochondrial health in obesity
    Chantal A. Pileggi, Breana G. Hooks, Ruth McPherson, Robert R.M. Dent, Mary-Ellen Harper
    Clinical Science.2022; 136(14): 1081.     CrossRef
  • A Study on Weight Loss Cause as per the Side Effect of Liraglutide
    Jin Yu, Jeongmin Lee, Seung-Hwan Lee, Jae-Hyung Cho, Hun-Sung Kim, Heng Zhou
    Cardiovascular Therapeutics.2022; 2022: 1.     CrossRef
Close layer
Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies
Shinje Moon, Hye Soo Chung, Jae Myung Yu, Hyung Joon Yoo, Jung Hwan Park, Dong Sun Kim, Young Joo Park
Endocrinol Metab. 2018;33(4):473-484.   Published online November 30, 2018
  • 8,693 View
  • 120 Download
  • 61 Web of Science
  • 60 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   

Epidemiological studies have suggested an association between Hashimoto thyroiditis (HT) and papillary thyroid cancer (PTC) development. Other studies, however, have reported a protective role of HT against PTC progression. Through this updated meta-analysis, we aimed to clarify the effects of HT on the progression of PTC.


We searched citation databases, including PubMed and Embase, for relevant studies from inception to September 2017. From these studies, we calculated the pooled odds ratios (ORs) of clinicopathologic features and the relative risk (RR) of PTC recurrence with 95% confidence intervals (CIs) using the Mantel-Haenszel method. Additionally, the Higgins I2 statistic was used to test for heterogeneity.


The meta-analysis included 71 published studies with 44,034 participants, among whom 11,132 had HT. We observed negative associations between PTC with comorbid HT and extrathyroidal extension (OR, 0.74; 95% CI, 0.68 to 0.81), lymph node metastasis (OR, 0.82; 95% CI, 0.72 to 0.94), distant metastasis (OR, 0.49; 95% CI, 0.32 to 0.76), and recurrence (RR, 0.50; 95% CI, 0.41 to 0.61).


In this meta-analysis, PTC patients with HT appeared to exhibit more favorable clinicopathologic characteristics and a better prognosis than those without HT.


Citations to this article as recorded by  
  • Malignancy risk of indeterminate lymph node at the central compartment in patients with thyroid cancer and concomitant sonographic thyroiditis
    Jung Hyo Rhim, Ji Ye Lee, Sun‐Won Park, Younghen Lee, So Lyung Jung, Tae Jin Yun, Eun Ju Ha, Jung Hwan Baek, Jinna Kim, Dong Gyu Na, Ji‐hoon Kim
    Head & Neck.2024; 46(8): 1922.     CrossRef
  • Hashimoto Thyroiditis and Mortality in Patients with Differentiated Thyroid Cancer: The National Epidemiologic Survey of Thyroid Cancer in Korea and Meta-Analysis
    Injung Yang, Jae Myung Yu, Hye Soo Chung, Yoon Jung Kim, Yong Kyun Roh, Min Kyu Choi, Sung-ho Park, Young Joo Park, Shinje Moon
    Endocrinology and Metabolism.2024; 39(1): 140.     CrossRef
  • Interaction of BANCR in the relationship between Hashimoto’s thyroiditis and papillary thyroid carcinoma expression patterns and possible molecular mechanisms
    Jiabo Zhang, Lingli Yao, Yu Guo
    The Journal of Gene Medicine.2024;[Epub]     CrossRef
  • Association between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis
    Jie Liu
    Clinical Thyroidology®.2024; 36(1): 26.     CrossRef
  • Predicting central cervical lymph node metastasis in papillary thyroid carcinoma with Hashimoto’s thyroiditis: a practical nomogram based on retrospective study
    Lirong Wang, Lin Zhang, Dan Wang, Jiawen Chen, Wenxiu Su, Lei Sun, Jue Jiang, Juan Wang, Qi Zhou
    PeerJ.2024; 12: e17108.     CrossRef
  • Nomogram to predict central lymph node metastasis in papillary thyroid carcinoma
    Dehui Qiao, Xian Deng, Ruichen Liang, Xu Li, Rongjia Zhang, Zhi Lei, Hui Yang, Xiangyu Zhou
    Clinical & Experimental Metastasis.2024;[Epub]     CrossRef
  • Utilizing Immunoglobulin G4 Immunohistochemistry for Risk Stratification in Patients with Papillary Thyroid Carcinoma Associated with Hashimoto Thyroiditis
    Faridul Haq, Gyeongsin Park, Sora Jeon, Mitsuyoshi Hirokawa, Chan Kwon Jung
    Endocrinology and Metabolism.2024; 39(3): 468.     CrossRef
  • Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules 2024
    Young Joo Park, Eun Kyung Lee, Young Shin Song, Su Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung,
    International Journal of Thyroidology.2024; 17(1): 208.     CrossRef
  • Predictors of lateral lymph node metastasis and skip metastasis in patients with papillary thyroid microcarcinoma
    Jee Hee Yoon, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Risk prediction for central lymph node metastasis in isolated isthmic papillary thyroid carcinoma by nomogram: A retrospective study from 2010 to 2021
    Yu Zhao, Wei Shi, Fang Dong, Xiuhua Wang, Chong Lu, Chunping Liu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The evaluation of locoregional tumoral involvement in the cooccurrence of hashimoto thyroiditis with papillary thyroid cancer: a case controlled study
    Shirzad Nasiri, Seyed Mostafa Meshkati Yazd, Mahsa Gholami, Sepehr Shahriarirad, Sina Sharghi, Reza Shahriarirad
    BMC Endocrine Disorders.2023;[Epub]     CrossRef
  • Hashimoto’s Thyroiditis: A Protective Factor against Recurrence in BRAF-Wild Type Differentiated Thyroid Carcinoma
    Peter P. Issa, Mahmoud Omar, Yusef Buti, Mohamed Aboueisha, Ruhul Munshi, Mohammad Hussein, Muhib Haidari, Graham Blair, Chad P. Issa, Mohamed Shama, Eman Toraih, Emad Kandil
    Cancers.2023; 15(8): 2371.     CrossRef
    K. V. Pivtorak, O. V Ivanhuk O. V
    Bulletin of Problems Biology and Medicine.2023; 1(1): 44.     CrossRef
  • Does the Association of Hashimoto's Thyroiditis with Differentiated Thyroid Cancer Really Have a Protective Role?
    Ahmet Numan Demir, Zehra Kara, Cem Sulu, Serhat Uysal, Serdar Sahin, Guldana Zulfaliyeva, Oznur Aydin Atar, Nahida Valikhanova, Tulin Ozturk, Hande Mefkure Ozkaya, Mustafa Sait Gonen
    Hormone and Metabolic Research.2023; 55(06): 388.     CrossRef
  • Ultrasound, laboratory and histopathological insights in diagnosing papillary thyroid carcinoma in a paediatric population: a single centre follow-up study between 2000-2022
    Dominika Januś, Małgorzata Wójcik, Anna Taczanowska-Niemczuk, Aleksandra Kiszka-Wiłkojć, Monika Kujdowicz, Małgorzata Czogała, Wojciech Górecki, Jerzy B. Starzyk
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer
    Havva Sezer, Dilek Yazıcı, Tarık Terzioğlu, Serdar Tezelman, Hande Bulut Canbaz, Aslıhan Yerlikaya, Mehmet Onur Demirkol, Yersu Kapran, Bülent Çolakoğlu, Eda Nur Çilingiroğlu, Faruk Alagöl
    The American Surgeon™.2023; 89(12): 5996.     CrossRef
  • 2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules
    Young Joo Park, Eun Kyung Lee, Young Shin Song, Soo Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung
    International Journal of Thyroidology.2023; 16(1): 1.     CrossRef
  • Clonal redemption of B cells in cancer
    Tyler R. McCaw, Serena Y. Lofftus, Joseph G. Crompton
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto’s thyroiditis: a systematic review with meta-analysis
    Lukasz Janicki, Agastya Patel, Jarosław Jendrzejewski, Andrzej Hellmann
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The role of vascular endothelial growth factor in the development of papillary thyroid carcinoma in patients with lymphocytic thyroiditis
    Minerva Endocrinology.2023;[Epub]     CrossRef
  • Chronic Lymphocytic Thyroiditis and Aggressiveness of Pediatric Differentiated Thyroid Cancer
    Richard M. Yeker, Amber D. Shaffer, Pushpa Viswanathan, Selma F. Witchel, Kevin Mollen, Linwah Yip, Sara E. Monaco, Umamaheswar Duvvuri, Jeffrey P. Simons
    The Laryngoscope.2022; 132(8): 1668.     CrossRef
  • Bisphenol A drives di(2-ethylhexyl) phthalate promoting thyroid tumorigenesis via regulating HDAC6/PTEN and c-MYC signaling
    Xuan Zhang, Nan Guo, Hao Jin, Renqi Liu, Zhen Zhang, Cheng Cheng, Zhijun Fan, Guopei Zhang, Mingyang Xiao, Shengwen Wu, Yuejiao Zhao, Xiaobo Lu
    Journal of Hazardous Materials.2022; 425: 127911.     CrossRef
  • Squamous Differentiation in the Thyroid: Metaplasia, Neoplasia, or Bystander?
    Meagan A. Chambers, Peter M. Sadow, Darcy A. Kerr
    International Journal of Surgical Pathology.2022; 30(4): 385.     CrossRef
  • Vitamin D Implications and Effect of Supplementation in Endocrine Disorders: Autoimmune Thyroid Disorders (Hashimoto’s Disease and Grave’s Disease), Diabetes Mellitus and Obesity
    Dorina Galușca, Mihaela Popoviciu, Emilia Babeș, Mădălina Vidican, Andreea Zaha, Vlad Babeș, Alexandru Jurca, Dana Zaha, Florian Bodog
    Medicina.2022; 58(2): 194.     CrossRef
  • Central Compartment Lymph Nodes Have Distinct Metastatic Patterns in Different Age Groups
    Caigu Yan, Xianghui He, Zuoyu Chen, Yizeng Wang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Synchronous occurrence of papillary thyroid microcarcinoma, medullary thyroid carcinoma and Hashimoto thyroiditis in a single thyroid: A case report with literature review
    Ari M. Abdullah, Rawa M. Ali, Karzan M. Salih, Karukh K. Mohammed, Fahmi H. Kakamad, Abdulwahid M. Salih
    International Journal of Surgery Case Reports.2022; 93: 106888.     CrossRef
  • Benign and malignant thyroid nodules with autoimmune thyroiditis
    Georgia N. Kassi, Catherine C. Evangelopoulou, Konstantinos D. Papapostolou, Helen J. Karga
    Archives of Endocrinology and Metabolism.2022;[Epub]     CrossRef
  • Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis
    Qizhi Tang, Weiyu Pan, Liangyue Peng, Francis Moore
    PLOS ONE.2022; 17(6): e0269995.     CrossRef
  • A Narrative Review of Preventive Central Lymph Node Dissection in Patients With Papillary Thyroid Cancer - A Necessity or an Excess
    David D. Dolidze, Alexey V. Shabunin, Robert B. Mumladze, Arshak V. Vardanyan, Serghei D. Covantsev, Alexander M. Shulutko, Vasiliy I. Semikov, Khalid M. Isaev, Airazat M. Kazaryan
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Role of papillary thyroid carcinoma patients with Hashimoto thyroiditis: evaluation of oxidative stress and inflammatory markers
    Natália Medeiros Dias Lopes, Hannah Hamada Mendonça Lens, Walison Augusto da Silva Brito, Julya Karen Bianchi, Poliana Camila Marinello, Rubens Cecchini, André Armani, Alessandra Lourenço Cecchini
    Clinical and Translational Oncology.2022; 24(12): 2366.     CrossRef
  • Emerging trends and hot spots in autoimmune thyroiditis research from 2000 to 2022: A bibliometric analysis
    Qiuxian Li, Wanyu Yang, Jiashu Li, Zhongyan Shan
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis
    Fabiana Pani, Paola Caria, Yoshinori Yasuda, Miyara Makoto, Stefano Mariotti, Laurence Leenhardt, Solmaz Roshanmehr, Patrizio Caturegli, Camille Buffet
    Cancers.2022; 14(17): 4287.     CrossRef
  • Comprehensive analysis of lncRNA-mediated ceRNA regulatory networks and key genes associated with papillary thyroid cancer coexistent with Hashimoto’s thyroiditis
    Yuepeng Zhang, Yueli Tian
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • Elastographic Evaluation of Thyroid Nodules in Children and Adolescents with Hashimoto’s Thyroiditis and Nodular Goiter with Reference to Cytological and/or Histopathological Diagnosis
    Hanna Borysewicz-Sańczyk, Beata Sawicka, Filip Bossowski, Janusz Dzięcioł, Artur Bossowski
    Journal of Clinical Medicine.2022; 11(21): 6339.     CrossRef
  • Prognostic value of the preoperative and early trends in postoperative serum thyroglobulin antibody levels among patients with papillary thyroid carcinoma and concomitant Hashimoto’s thyroiditis
    Siyuan Xu, Hui Huang, Jiaxin Qian, Xiaolei Wang, Zhengang Xu, Shaoyan Liu, Jie Liu
    Endocrine.2022; 80(2): 392.     CrossRef
  • What has changed in the last 20 years in the postoperative specimen findings of the papillary thyroid cancer cases? A retrospective analysis
    Burak Bakar, Pınar Taşar, Turkay Kırdak, Sadık Kılıçturgay
    Turkish Journal of Surgery.2022; 38(4): 345.     CrossRef
  • A nomogram model based on the preoperative clinical characteristics of papillary thyroid carcinoma with Hashimoto's thyroiditis to predict central lymph node metastasis
    Wanjun Zhao, Linye He, Jingqiang Zhu, Anping Su
    Clinical Endocrinology.2021; 94(2): 310.     CrossRef
  • The Association of Histologically Proven Chronic Lymphocytic Thyroiditis with Clinicopathological Features, Lymph Node Metastasis, and Recurrence Rates of Differentiated Thyroid Cancer
    Berna İmge Aydoğan, Adile Begüm Bahçecioğlu Mutlu, Seher Yüksel, Sevim Güllü, Rıfat Emral, Özgür Demir, Mustafa Şahin, Vedia Tonyukuk Gedik, Demet Çorapçıoğlu, Serpil Dizbay Sak, Murat Faik Erdoğan
    Endocrine Pathology.2021; 32(2): 280.     CrossRef
  • Beneficial autoimmunity improves cancer prognosis
    Laurence Zitvogel, Claude Perreault, Olivera J. Finn, Guido Kroemer
    Nature Reviews Clinical Oncology.2021; 18(9): 591.     CrossRef
  • Influence Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: Hashimoto’s Thyroiditis Has a Weak Effect on Central or Lateral Lymph Node Metastasis
    Liguang Zhou, Gang Chen, Lei Sheng, Nan Liu, Bin Zhang, Qingdong Zeng, Bo Chen
    Cancer Management and Research.2021; Volume 13: 3953.     CrossRef
  • Implications of a background of Hashimoto’s thyroiditis on the current conservative surgical trend towards papillary thyroid carcinoma
    Shadi Hamouri, Sohail Bakkar, Almoutuz Aljaafreh, Mohammed Bani Hani, Hussein Heis, Ghazi Qasaimeh, Nasr Alrabadi, Wisam Al Gargaz, Haitham Odat, Yazan Alkurdi, Tarek Manasreh, Mohammad Matalka, Moamin Badwan
    Updates in Surgery.2021; 73(5): 1931.     CrossRef
  • Thyroid nodules in childhood‐onset Hashimoto's thyroiditis: Frequency, risk factors, follow‐up course and genetic alterations of thyroid cancer
    Yun Jeong Lee, Yeon Jin Cho, You Joung Heo, Eun‐Jae Chung, Young Hun Choi, Jong‐Il Kim, Young Joo Park, Choong Ho Shin, Young Ah Lee
    Clinical Endocrinology.2021; 95(4): 638.     CrossRef
  • Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes
    Siyuan Xu, Hui Huang, Jiaxin Qian, Yang Liu, Ying Huang, Xiaolei Wang, Shaoyan Liu, Zhengang Xu, Jie Liu
    JAMA Network Open.2021; 4(7): e2118526.     CrossRef
  • The Effects of Chronic Lymphocytic Thyroiditis on Clinicopathologic Factors in Papillary Thyroid Cancer
    Davut Sakiz, Muhammed Erkam Sencar, Murat Calapkulu, Ilknur Ozturk Unsal, Levent Aktas, Bekir Ucan, Mustafa Ozbek, Erman Cakal
    Endocrine Practice.2021; 27(12): 1199.     CrossRef
  • Significance of DMBT1 in Papillary Thyroid Carcinoma Concurrent With Hashimoto’s Thyroiditis
    Xiao-xiong Gan, Ya-yi Li, Si-jin Li, Shi-sen Mo, Jian-hua Feng, Fei Shen, Wen-song Cai, Ye-qian Lai, Bo Xu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Pre-existing Thyroiditis Ameliorates Papillary Thyroid Cancer: Insights From a New Mouse Model
    Fabiana Pani, Yoshinori Yasuda, Giulia Di Dalmazi, Paulina Chalan, Kathleen Gabrielson, Luigi Adamo, Elena Sabini, Stefano Mariotti, Patrizio Caturegli
    Endocrinology.2021;[Epub]     CrossRef
  • Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma
    Juliette Paillet, Céleste Plantureux, Sarah Lévesque, Julie Le Naour, Gautier Stoll, Allan Sauvat, Pamela Caudana, Jimena Tosello Boari, Norma Bloy, Sylvie Lachkar, Isabelle Martins, Paule Opolon, Andrea Checcoli, Agathe Delaune, Noémie Robil, Pierre de l
    Journal of Experimental Medicine.2021;[Epub]     CrossRef
  • Papillary Thyroid Cancer Prognosis: An Evolving Field
    Salvatore Ulisse, Enke Baldini, Augusto Lauro, Daniele Pironi, Domenico Tripodi, Eleonora Lori, Iulia Catalina Ferent, Maria Ida Amabile, Antonio Catania, Filippo Maria Di Matteo, Flavio Forte, Alberto Santoro, Piergaspare Palumbo, Vito D’Andrea, Salvator
    Cancers.2021; 13(21): 5567.     CrossRef
  • Overexpression of PD-L1 in Papillary Carcinoma and Its Association with Clinicopathological Variables
    Servet KOCAÖZ, Gülay TURAN
    Düzce Tıp Fakültesi Dergisi.2021; 23(3): 252.     CrossRef
  • Correlation Between Hashimoto's Thyroiditis–Related Thyroid Hormone Levels and 25-Hydroxyvitamin D
    Guanqun Chao, Yue Zhu, Lizheng Fang
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Oncological impact of hypothyroidism and levothyroxine supplementation following hemithyroidectomy in patients with papillary thyroid carcinoma
    Dongbin Ahn, Gil J. Lee, Jin H. Sohn, Jae H. Jeon
    Head & Neck.2020; 42(5): 1004.     CrossRef
  • Suspicious ultrasound characteristics correlate with multiple factors that predict central lymph node metastasis of papillary thyroid carcinoma: Significant role of HBME-1
    Li Jianming, Liu Jibin, Qian Linxue
    European Journal of Radiology.2020; 123: 108801.     CrossRef
  • Unexpected high‐risk pathologic features following thyroidectomy in the chinese immigrant population
    Arvind K. Badhey, Erin Moshier, Ameya Jategaonkar, Anni Wong, Kristen Echanique, Raymond L. Chai
    The Laryngoscope.2020; 130(7): 1844.     CrossRef
  • Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links
    Oksana Sulaieva, Oleksii Selezniov, Dmytro Shapochka, Nataliia Belemets, Oleksandr Nechay, Yelizaveta Chereshneva, Dibakhan Tsomartova, Marina Ivanova
    Heliyon.2020; 6(1): e03077.     CrossRef
  • Changes in Treg numbers and activity in papillary thyroid carcinoma with and without Hashimoto’s thyroiditis
    Na Zhao, Xin Liu, Chao Wu, Yuanchao Liu, Xiangnan Zhao, Xianghui He
    Journal of International Medical Research.2020; 48(4): 030006052091922.     CrossRef
  • Genetic relationship between Hashimoto`s thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto`s thyroiditis
    Ohoud Subhi, Hans-Juergen Schulten, Nadia Bagatian, Roa'a Al-Dayini, Sajjad Karim, Sherin Bakhashab, Reem Alotibi, Alaa Al-Ahmadi, Manar Ata, Aisha Elaimi, Saad Al-Muhayawi, Majid Mansouri, Khalid Al-Ghamdi, Osman Abdel Hamour, Awatif Jamal, Jaudah Al-Mag
    PLOS ONE.2020; 15(6): e0234566.     CrossRef
  • Hashimoto's thyroiditis as a risk factor for thyroid cancer
    Ulla Feldt-Rasmussen
    Current Opinion in Endocrinology, Diabetes & Obesity.2020; 27(5): 364.     CrossRef
  • Predictive Factors of Recurrence for Multifocal Papillary Thyroid Microcarcinoma With Brafv600e Mutation: A Single Center Study of 1,207 Chinese Patients
    Shuai Xue, Li Zhang, Peisong Wang, Jia Liu, Yue Yin, Meishan Jin, Liang Guo, Yuhua Zhou, Guang Chen
    Frontiers in Endocrinology.2019;[Epub]     CrossRef
  • Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy
    Francesca Ragusa, Poupak Fallahi, Giusy Elia, Debora Gonnella, Sabrina Rosaria Paparo, Claudia Giusti, Leonid P. Churilov, Silvia Martina Ferrari, Alessandro Antonelli
    Best Practice & Research Clinical Endocrinology & Metabolism.2019; 33(6): 101367.     CrossRef
  • Características anatomopatológicas del carcinoma papilar de tiroides en especimenes con y sin tiroiditis linfocitica crónica.
    Carlos Osorio Covo, Jorge Ballestas Barrera, Jorge Martínez Castro, Zully Acevedo Meza, Diego Barrios Castellar, Francisco Herrera Sáenz, Cesar Redondo Bermúdez, Katherine Redondo De Oro
    Revista Ciencias Biomédicas.2019; 8(2): 32.     CrossRef
Close layer
Sustained Maintenance of Normal Insulin-like Growth Factor-I during Pregnancy and Successful Delivery in an Acromegalic Patient with Octreotide-LAR(R) Treatment.
Soo Kyoung Kim, Jung Hwa Jung, Jae Hyeon Kim, Kyu Yeon Hur, Alice Hyun Tan, Hee Kyung Kim, Ji In Lee, Hye Soo Chung, Kwang Won Kim
Endocrinol Metab. 2010;25(3):213-216.   Published online September 1, 2010
  • 2,003 View
  • 23 Download
AbstractAbstract PDF
We report here on a 34-year-old Korean woman with active acromegaly and who received Octreotide-LAR(R) for 12 months following transsphenoidal pituitary surgery. During Octreotide-LAR(R) treatment, the clinical improvement was paralleled with the decrease of the growth hormone levels to 1.1 ng/mL and the insulin-like growth factor-I (IGF-I) levels to 345.5 ng/mL. Octreotide-LAR(R) was discontinued when the patient was found to be at the 12th week of pregnancy. During pregnancy, the patient experienced clinical well-being and she maintained her IGF-I levels within the normal range for her age-matched despite discontinuation of Octreotide-LAR(R) treatment at early gestation. She delivered a full-term healthy male infant. The serum IGF-I levels of the patient increased progressively increased after delivery. This report describes a successful pregnancy in an acromegalic woman who was exposed to Octreotide-LAR(R) during the early gestational period. She and who showed an unexpected pattern of persistently normal IGF-I levels through the pregnancy despite discontinuation of Octreotide-LAR(R) therapy.
Close layer
Two Cases of Acromegaly with Empty Sella Syndrome Treated by Long-Acting Release Octreotide.
Dong Jin Kim, Young Jin Seo, Nam Hoon Kim, Hye Soo Chung, Chai Ryoung Eun, Hye Jung Choi, Hye Sook Kim, Sae Jeong Yang, Juri Park, Hye Jin Yoo, Soo Yeon Park, Yun Jeong Lee, Ohk Hyun Ryu, Kye Won Lee, Hee Young Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2007;22(2):135-141.   Published online April 1, 2007
  • 2,161 View
  • 28 Download
AbstractAbstract PDF
Two cases of typical acromegaly with empty sella syndrome presented to our institution. In the natural course of untreated pituitary adenoma, empty sella syndrome may result from necrosis by infarction or from hemorrhage of the pituitary gland. In our patients, the secretion of growth hormone continued in spite of the existence of empty sella syndrome. In one case, we confirmed the hypersecretion of growth hormone from sella by jugular vein sampling. Medical therapy with somatostatin analogue was attempted because there was no obvious mass in the sella. After 6~12 months of treatment with long-acting release octreotide, clinical features in our patients were improved, and the level of growth hormone and IGF-1 were also normalized.
Close layer

Endocrinol Metab : Endocrinology and Metabolism